• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.勘误：循环中高浓度的音猬因子蛋白与接受酪氨酸激酶抑制剂治疗的EGFR突变晚期非小细胞肺癌的不良预后相关。
Front Oncol. 2022 Feb 9;12:852540. doi: 10.3389/fonc.2022.852540. eCollection 2022.
2
High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.循环中 Sonic Hedgehog 蛋白水平高与酪氨酸激酶抑制剂治疗的 EGFR 突变晚期非小细胞肺癌预后不良相关。
Front Oncol. 2021 Dec 14;11:747692. doi: 10.3389/fonc.2021.747692. eCollection 2021.
3
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
4
Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.刺猬信号通路的激活介导非小细胞肺癌对表皮生长因子受体抑制剂的耐药性。
J Cancer. 2022 Jan 4;13(3):987-997. doi: 10.7150/jca.63410. eCollection 2022.
5
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
6
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.抑制Hedgehog信号通路可协同增强非小细胞肺癌细胞系对表皮生长因子受体酪氨酸激酶抑制剂的敏感性。
PLoS One. 2016 Mar 4;11(3):e0149370. doi: 10.1371/journal.pone.0149370. eCollection 2016.
7
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.悉尼西南部地方卫生区晚期表皮生长因子受体突变型非小细胞肺癌患者的临床结局
Intern Med J. 2017 Dec;47(12):1405-1411. doi: 10.1111/imj.13555.
8
The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的相关性：94例EGFR突变患者的回顾性评估
Oncotarget. 2017 Jan 10;8(2):3412-3421. doi: 10.18632/oncotarget.13787.
9
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.在表皮生长因子受体酪氨酸激酶抑制剂治疗后出现脑膜转移的 EGFR 突变型非小细胞肺癌中重新挑战治疗。
Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14.
10
Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.表皮生长因子受体靶向免疫磁脂质体用于表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌循环肿瘤细胞计数。
Lung Cancer. 2019 Jun;132:45-53. doi: 10.1016/j.lungcan.2019.04.003. Epub 2019 Apr 5.

勘误：循环中高浓度的音猬因子蛋白与接受酪氨酸激酶抑制剂治疗的EGFR突变晚期非小细胞肺癌的不良预后相关。

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.

作者信息

Takam Kamga Paul, Swalduz Aurélie, Costantini Adrien, Julié Catherine, Emile Jean-François, Pérol Maurice, Avrillon Virginie, Ortiz-Cuaran Sandra, De Saintigny Pierre, Giroux-Leprieur Etienne

机构信息

Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.

Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

出版信息

Front Oncol. 2022 Feb 9;12:852540. doi: 10.3389/fonc.2022.852540. eCollection 2022.

DOI:10.3389/fonc.2022.852540
PMID:35223530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8867316/
Abstract

[This corrects the article DOI: 10.3389/fonc.2021.747692.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fonc.2021.747692。]